Association of Tumor Necrosis Factor-α and Myeloperoxidase enzyme with Severe Asthma: A comparative study

Ahmed Khalid Aldhalmi1, Ali Jihad Hemid Al-Athari2, Hayder Abdul-Amir Makki Al-Hindy3

  • 1The University of Mashreq, College of Pharmacy, Baghdad, Iraq.

Abstract

Insights

Myeloperoxidase (MPO) levels are higher in asthma patients, while Tumor Necrosis Factor-alpha (TNF-α) is lower, except in severe cases. MPO shows better diagnostic potential for asthma than TNF-α.

Area of Science:

  • Immunology
  • Pulmonology
  • Biomarker Discovery

Background:

  • Asthma involves airway hyperresponsiveness, potentially influenced by neutrophils.
  • Neutrophil activity can be indirectly assessed via myeloperoxidase (MPO) activity.
  • Limited research exists on the combined role of serum Tumor Necrosis Factor-alpha (TNF-α) and MPO in asthma.

Purpose of the Study:

  • To investigate the combined association of serum TNF-α and MPO with asthma.
  • To evaluate the diagnostic accuracy of TNF-α and MPO in distinguishing asthma patients from healthy controls.

Main Methods:

  • A case-control study involving 110 asthma patients and 92 controls.
  • Serum samples analyzed for TNF-α and MPO using immunoassays.
  • Pulmonary function tests (FEV1%, PEF/L) and ROC curve analysis were performed.

Main Results:

  • Asthma patients exhibited significantly higher MPO levels (p=0.00), while controls had higher TNF-α levels (p=0.006).
  • TNF-α levels were significantly higher in severe asthmatics compared to mild/moderate cases.
  • MPO demonstrated a significant predictive capacity for distinguishing asthma, outperforming TNF-α in sensitivity, specificity, and accuracy.

Conclusions:

  • MPO is a more effective biomarker than TNF-α for diagnosing asthma.
  • TNF-α may contribute to neutrophilic inflammation in severe asthma.
  • Further research is warranted to explore the specific roles of these biomarkers in asthma pathogenesis.

Related Concept Videos

Asthma-II: Pathophysiology and Classification01:26

Asthma-II: Pathophysiology and Classification

Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.8K
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
533
Chronic Obstructive Pulmonary Disease-II: Pathophysiology01:20

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
2.9K
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.6K
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
417